DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

DexCom reported FY2025 revenue of nearly $4.7B, up 15.6%, with net income of about $836.3M and free cash flow near $1.1B, while Insulet posted FY2025 revenue just over $2.7B, up 30.9%, and net income of roughly $354.4M. The article argues Insulet is the better 2026 buy due to lower valuation, at 22.0x forward P/E and 3.6x P/S versus DexCom at 28.4x and 6.1x. Key risks include DexCom’s FDA warning letter and GLP-1 pressure, plus Insulet’s dependence on Omnipod and sensor partnerships.

Analysis

PODD is the cleaner 2026 growth/value compounder because the market is still under-penetrated, but the real second-order benefit is that it monetizes treatment intensity, not just diagnosis. If GLP-1 adoption lowers glucose-check frequency, that is a headwind for CGM growth rates before it becomes a demand destruction story for pump adoption; the device that changes insulin delivery behavior should prove stickier than the one that only measures the consequence. That shifts the burden of proof onto DXCM to keep expanding beyond a maturing monitoring category while also clearing manufacturing/regulatory overhangs.

The competitive moat story is also asymmetric. DXCM is more exposed to premium-brand price pressure from larger incumbents and to any channel disruption from quality remediation, which can show up as delayed hospital wins and slower international rollouts over the next 2-4 quarters. PODD’s key vulnerability is concentration in the Omnipod platform, but the bigger issue is dependency on ecosystem partners for sensor compatibility; if those relationships become commercially less favorable, PODD could lose attachment rates even if unit demand stays strong.

The valuation gap looks justified, but not large enough to ignore execution risk. PODD screens cheaper because the market is discounting platform concentration and a longer adoption curve in type 2 diabetes, yet that same curve gives it more optionality if education and reimbursement improve over 12-24 months. Consensus may be underestimating how much of the next leg in diabetes tech is a utilization story rather than a unit-growth story: the winner is the company that turns first-time users into recurring protocol users.

The contrarian view is that DXCM may be the better short-term squeeze if regulatory noise proves contained, because its quality issues are already visible while PODD’s valuation depends on continued near-flawless execution. But over a full 12-18 month horizon, PODD offers the better risk-adjusted asymmetry: cheaper multiple, faster top-line growth, and a larger addressable upgrade cycle if automated insulin delivery broadens beyond early adopters.

Key Decisions for Investors

• Long PODD vs short DXCM for a 6-12 month relative-value trade; target PODD outperformance if type 2 adoption and partner integration remain intact, with downside capped by DXCM regulatory overhang resolution.
• Buy PODD on pullbacks rather than strength; preferred entry is any 8-12% drawdown from recent highs, with a 12-24 month hold for penetration gains to re-rate the multiple.
• Use DXCM as a tactical long only if the market overreacts to regulatory headlines; the trade works best on a 1-3 month horizon and should be cut if remediation milestones slip into the next earnings cycle.
• For options, consider a PODD call spread 9-12 months out to express upside while limiting premium burn; this fits a base-case re-rating without paying full outright volatility.
• Avoid a broad basket bet on diabetes hardware; prefer pair structures because GLP-1 adoption creates uneven winners, with monitoring exposed first and treatment platforms showing better durability.